Webcast on Demand
On demand webcast: View the webcast from the Boehringer Ingelheim press conference at the ESC 2009 in Barcelona on 30 August.
Value through Innovation17 January 2013
Stroke Prevention in Atrial Fibrillation (SPAF) News and Information
This section includes information and resources about Stroke Prevention in Atrial Fibrillation (SPAF) for journalists: Boehringer Ingelheim press releases, background information, related press kits and a collection of images and videos.
Stroke Prevention in Atrial Fibrillation (SPAF) Press Releases
| 27.08.2012 |
Clinical experience with Pradaxa® crosses one million patient-years of treatment - For Non-US, Non-UK & Non-Canadian Media Only |
|---|---|
| 24.08.2012 |
Cost effectiveness and clinical efficacy of Pradaxa® (dabigatran etexilate) versus rivaroxaban analysed - For Non-US, Non-UK & Non-Canadian Media Only |
| 20.06.2012 |
First study to evaluate alternative to warfarin for mechanical heart valve patients launched with Pradaxa® (dabigatran etexilate) - For Non-US, Non-UK & Non-Canadian Media Only |
| 18.06.2012 |
AF patients who require surgery benefit from a shorter treatment interruption on dabigatran etexilate (Pradaxa®) compared to warfarin - For Non-US, Non-UK & Non-Canadian Media Only |
| 06.06.2012 |
FDA affirms superiority of Pradaxa® (dabigatran etexilate) 150mg over warfarin in reduction of both ischaemic and haemorrhagic strokes - For Non-US, Non-UK & Non-Canadian Media Only |
SPAF Related News Room
SPAF Related Documents
Videos
-
-
Prof. Gregory Lip
- Watch the video(QT)
-
-
-
-
-
-
-
-
-
-
-
